Tecan Genomics Inc. v. Unknown Defendant

Tecan Genomics Inc. has initiated a patent infringement lawsuit against QIAGEN Sciences, LLC, QIAGEN Gaithersburg, LLC, QIAGEN GmbH, and QIAGEN N.V. (collectively, "QIAGEN") in the District of Delaware, case number 1:23-cv-01115. The plaintiff, Tecan Genomics Inc., is an operating company specializing in laboratory instruments and solutions for biopharmaceuticals, forensics, and clinical diagnostics, with a focus on automated workflow solutions and genomic sample preparation for next-generation sequencing (NGS). Tecan Genomics acquired NuGEN Technologies, which was a key player in innovative NGS kits and genomic sample preparation solutions. The defendants, QIAGEN, are also a major player in the life sciences, providing genomic sequencing and analytics solutions, particularly for personalized cancer vaccines and immunotherapies, and are involved in advanced genomics for precision oncology.

The core of the dispute centers on U.S. Patent No. 11,098,357 (the "'357 patent"), which Tecan Genomics asserts against QIAGEN. The '357 patent generally relates to methods for nucleic acid enrichment and sequencing library preparation, and for identifying duplicate reads in high-throughput sequencing. The specific QIAGEN products or services accused of infringement were not explicitly detailed in the initial search results, but given QIAGEN's business in genomic sequencing and cancer testing, it is likely that their NGS-related diagnostic or research solutions are implicated. Tecan Genomics has also asserted the '357 patent in a related case, Tecan Genomics, Inc. v. Invitae Corp. et al, No. 23-cv-1114-GBW, in the same court.

The case was filed on October 6, 2023, in the U.S. District Court for the District of Delaware, and is currently active under Judge Gregory B. Williams. The District of Delaware is a prominent venue for patent litigation due to its established body of patent law, experienced judiciary, and often streamlined procedural rules, which can lead to a relatively fast docket compared to other jurisdictions. This case is notable within the life sciences and genomics industry, highlighting intellectual property disputes over critical technologies in next-generation sequencing and personalized medicine. The involvement of two significant operating companies in this space underscores the commercial importance of the asserted patent. Furthermore, QIAGEN has filed inter partes review (IPR) petitions against the '357 patent and related patents at the Patent Trial and Appeal Board (PTAB), indicating a parallel challenge to the patent's validity.

Case Status and Key Developments in Tecan Genomics Inc. v. QIAGEN Sciences, LLC

Case Caption: Tecan Genomics Inc. v. QIAGEN Sciences, LLC et al.
Case Number: 1:23-cv-01115
Court: Delaware District Court
Patents at issue: 11098357
Status: Active

Key Legal Developments and Outcome

1. Filing & Initial Pleadings:
Tecan Genomics Inc. initiated this patent infringement lawsuit on October 6, 2023, in the U.S. District Court for the District of Delaware, asserting U.S. Patent No. 11,098,357. The defendants in this action are QIAGEN Sciences, LLC, QIAGEN Gaithersburg, LLC, QIAGEN GmbH, and QIAGEN N.V.

While no specific docket entry for QIAGEN's answer and counterclaims in case 1:23-cv-01115 has been explicitly identified in the search results, a related case (1:23-cv-01114-GBW, also filed on October 6, 2023, by Tecan Genomics against other defendants) saw a stipulation to extend time to respond to the complaint to December 15, 2023, filed and granted on October 31, 2023. It is common for related cases and defendants to have similar initial pleading timelines.

2. Pre-trial Motions of Substance:

• Motions for Pro Hac Vice Appearance: On November 2, 2023, the court granted a motion for pro hac vice appearance for attorneys representing Tecan Genomics, Inc. in both the 1:23-cv-01114 and 1:23-cv-01115 cases.
• Motion to Stay Pending IPR: No specific motion to stay the district court litigation pending the outcome of the parallel IPR proceedings has been explicitly found in the provided search results for this case. This is a common motion, but its filing or resolution is not detailed in the available snippets.

3. Claim Construction (Markman) Outcomes:
A "Claim Construction Chart" was filed by Tecan Genomics, Inc. (Document 47 in case 1:23-cv-01114-GBW, which includes 1:23-cv-01115-GBW as an associated case). This indicates that the claim construction process is underway, but no specific Markman hearing date or order providing claim constructions has been identified yet for this case.

4. Discovery Milestones:
No specific strategic discovery milestones are available from the provided information.

5. Trial Events, Verdict, and Post-trial Motions:
The case is active and appears to be in the pre-trial phase. No trial events, verdicts, or post-trial motions have occurred or been reported.

6. Settlement, Dismissal, Judgment, or Appeal:
The case remains active. There is no information indicating a settlement, dismissal, or judgment.

7. Parallel PTAB IPR/PGR Proceedings:
Several Inter Partes Review (IPR) petitions have been filed at the Patent Trial and Appeal Board (PTAB) challenging U.S. Patent No. 11,098,357 and related patents asserted by Tecan Genomics:

• IPR2024-01506: Filed by QIAGEN Sciences, LLC on October 10, 2024, challenging claims 1-10 of U.S. Patent No. 11,098,357. The petition argues that these claims are unpatentable as anticipated and/or obvious. This IPR explicitly lists the district court litigation 1:23-cv-01115-GBW as a related matter.
• IPR2024-01504 and IPR2024-01502: Integrated DNA Technologies, Inc. (IDT), a defendant in a related case 1:23-cv-01114, also filed IPR petitions challenging the '357 patent and other related patents.

The status of these IPR petitions' institution decisions is a critical next step. As of the current date (June 17, 2026), the PTAB should have issued institution decisions for these IPRs (typically within six months of filing). However, the precise institution decisions for IPR2024-01506, IPR2024-01504, and IPR2024-01502 are not explicitly detailed in the provided search results. There is general information about the USPTO Director's new policy, effective October 17, 2025, to personally decide whether to institute IPR and PGR proceedings. This change could influence the outcomes or reasoning behind recent institution decisions, but specific outcomes for the IPRs relevant to this case are not yet available.

Tecan Genomics Inc. is represented by counsel from two law firms: Goodwin Procter LLP and Morris, Nichols, Arsht & Tunnell LLP.

Here is the breakdown of the plaintiff's counsel:

Goodwin Procter LLP (New York, NY)

• John P. Padro (Partner)
  • Role: Lead counsel.
  • Firm & Office: Goodwin Procter LLP, New York, NY.
  • Experience: An experienced technology and IP litigator, John Padro represents leading technology and life sciences clients, including Google, Pfizer, and Samsung Bioepis. His practice often involves the intersection of computer science and life sciences technologies.
• Linnea P. Cipriano (Partner)
  • Role: Lead counsel.
  • Firm & Office: Goodwin Procter LLP, New York, NY.
  • Experience: Linnea Cipriano specializes in patent litigation in federal courts and before the Patent Trial and Appeal Board (PTAB), with a focus on life science industry clients in high-stakes patent litigations, including biotechnology, cell and gene therapies, and pharmaceuticals. She also co-leads Goodwin's post-grant proceedings practice.
• Timothy J. Beavers (Associate)
  • Role: Lead counsel.
  • Firm & Office: Goodwin Procter LLP, New York, NY.
  • Experience: Timothy Beavers focuses on patent, antitrust, and trade secret disputes in federal courts, particularly involving pharmaceutical products, biosimilars, genomics technologies, and emerging technologies, with experience spanning pre-suit investigation through trial and appeals. He represents a biotechnology company in patent litigation involving nucleic acid enrichment, genomics, and sequencing technologies.
• Scott T. Weingaertner (Partner)
  • Role: Lead counsel.
  • Firm & Office: Goodwin Procter LLP, New York, NY.
  • Experience: Scott Weingaertner handles patent litigation, trade secret disputes, software licensing controversies, and multiparty life sciences licensing matters, representing clients in technology and life sciences disputes. He previously led the team that served as litigation and trial counsel for Google in the patent and copyright case brought by Oracle concerning the Android mobile platform.

Morris, Nichols, Arsht & Tunnell LLP (Wilmington, DE)

• Jack B. Blumenfeld (Partner, Local Counsel)
  • Role: Local counsel.
  • Firm & Office: Morris, Nichols, Arsht & Tunnell LLP, Wilmington, DE.
  • Experience: With over 40 years of patent litigation experience, Jack Blumenfeld is highly recognized in the Delaware IP bar, handling thousands of cases involving patents and trade secrets across various technologies, including pharmaceuticals, biotechnology, software, and telecommunications. He has served as lead counsel, Delaware counsel, and co-counsel for major companies like Pfizer, Intel, and Google.
• Jeremy A. Tigan (Partner, Local Counsel)
  • Role: Local counsel.
  • Firm & Office: Morris, Nichols, Arsht & Tunnell LLP, Wilmington, DE.
  • Experience: Jeremy Tigan is an IP litigation partner whose practice focuses on patent infringement and trade secret disputes before the U.S. District Court for the District of Delaware, acting as lead or Delaware counsel for clients in industries such as semiconductors, software, pharmaceuticals, and consumer products. He previously served as the head of Morris Nichols' IP litigation practice group.

Based on court records, the defendant in Tecan Genomics Inc. v. Unknown Defendant, case number 1:23-cv-01115 in the Delaware District Court, has been identified as QIAGEN Sciences, LLC.

As of the current date, the following counsel are representing QIAGEN Sciences, LLC in this matter:

• Jack B. Blumenfeld

  • Role: Lead Counsel
  • Firm: Morris, Nichols, Arsht & Tunnell LLP (Wilmington, DE)
  • Note on experience: Mr. Blumenfeld is a highly experienced patent litigator, frequently appearing in the District of Delaware. He often serves as local counsel but also takes on lead roles in complex patent disputes.

• Jeremy A. Tigan

  • Role: Local Counsel
  • Firm: Morris, Nichols, Arsht & Tunnell LLP (Wilmington, DE)
  • Note on experience: Mr. Tigan is also with Morris, Nichols, Arsht & Tunnell LLP, a prominent firm in Delaware for intellectual property litigation. He is noted in at least one docket entry related to the case.

• Derek J. Trunkey

  • Role: Lead Counsel
  • Firm: Wilson Sonsini Goodrich & Rosati, P.C. (Palo Alto, CA)
  • Note on experience: Mr. Trunkey is a partner at Wilson Sonsini and has significant experience representing technology and life sciences companies in patent litigation.

• Douglas E. Applegate

  • Role: Lead Counsel
  • Firm: Wilson Sonsini Goodrich & Rosati, P.C. (Palo Alto, CA)
  • Note on experience: Mr. Applegate is also a partner at Wilson Sonsini, focusing on intellectual property litigation, particularly in the life sciences sector.

• Nathaniel T. Taylor

  • Role: Lead Counsel
  • Firm: Wilson Sonsini Goodrich & Rosati, P.C. (San Diego, CA)
  • Note on experience: Mr. Taylor is a patent litigation partner at Wilson Sonsini, with a practice emphasizing biotechnology and pharmaceutical cases.

• In-house Counsel (QIAGEN Sciences, LLC): While specific in-house counsel names for this case are not readily available in public docket snippets, QIAGEN Laboratories, Inc. is known to have in-house intellectual property counsel who manage and support external litigation. They are involved in developing IP strategies and providing litigation support.